Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors.

ABSTRACT:

Importance

Immune checkpoint inhibitors can produce distinct toxic effects that require prompt recognition and timely management.

Objective

To develop a technology-enabled, dynamically adaptive protocol that can provide the accurate information needed to inform specific remedies for immune toxic effects in patients treated with immune checkpoint inhibitors.

Design, setting, and participants

An open-label cohort study was conducted at a single tertiary referral center from September 6, 2019, to September 3, 2020. The median follow-up duration was 63 (interquartile range, 35.5-122) days. Fifty patients with genitourinary cancers treated with immune checkpoint inhibitors were enrolled.

Interventions

A fit-for-purpose electronic platform was developed to enable act

SUBMITTER: Msaouel P 

PROVIDER: S-EPMC8406081 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature